89 related articles for article (PubMed ID: 12594278)
1. Selective induction of high avidity CTL by altering the balance of signals from APC.
Oh S; Hodge JW; Ahlers JD; Burke DS; Schlom J; Berzofsky JA
J Immunol; 2003 Mar; 170(5):2523-30. PubMed ID: 12594278
[TBL] [Abstract][Full Text] [Related]
2. Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface.
Dong S; Wang P; Zhao P; Chen M
Mol Pharm; 2017 Oct; 14(10):3312-3321. PubMed ID: 28789525
[TBL] [Abstract][Full Text] [Related]
3. Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway.
Pouniotis DS; Apostolopoulos V; Pietersz GA
Immunology; 2006 Mar; 117(3):329-39. PubMed ID: 16476052
[TBL] [Abstract][Full Text] [Related]
4. Sialic acid blockade in dendritic cells enhances CD8
Balneger N; Cornelissen LAM; Wassink M; Moons SJ; Boltje TJ; Bar-Ephraim YE; Das KK; Søndergaard JN; Büll C; Adema GJ
Cell Mol Life Sci; 2022 Jan; 79(2):98. PubMed ID: 35089436
[TBL] [Abstract][Full Text] [Related]
5. Immune Signature of Enhanced Functional Avidity CD8
Hu Z; Zhu L; Wang J; Wan Y; Yuan S; Chen J; Ding X; Qiu C; Zhang X; Qiu C; Xu J
Sci Rep; 2017 Feb; 7():41558. PubMed ID: 28155878
[TBL] [Abstract][Full Text] [Related]
6. CD40 activation enhances the magnitude of cellular immune responses against p53 but not the avidity of the effectors.
Erdile LF; Smith D
Cancer Immunol Immunother; 2000 Oct; 49(8):410-6. PubMed ID: 11043847
[TBL] [Abstract][Full Text] [Related]
7. Metabolic control of asyMYCtric division.
Do MH; Li MO
Cell Res; 2016 Aug; 26(8):863-4. PubMed ID: 27197568
[TBL] [Abstract][Full Text] [Related]
8. Multivalent virus-like epitope display amplifies BCR signaling independent of avidity.
Nat Immunol; 2023 Oct; 24(10):1610-1611. PubMed ID: 37723350
[No Abstract] [Full Text] [Related]
9. Biomechanics of T Cell Dysfunctions in Chronic Diseases.
Gunasinghe SD; Peres NG; Goyette J; Gaus K
Front Immunol; 2021; 12():600829. PubMed ID: 33717081
[TBL] [Abstract][Full Text] [Related]
10. Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.
Gilfillan CB; Hebeisen M; Rufer N; Speiser DE
Eur J Immunol; 2021 Jun; 51(6):1348-1360. PubMed ID: 33704770
[TBL] [Abstract][Full Text] [Related]
11. Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses.
Kumbhari A; Egelston CA; Lee PP; Kim PS
Front Immunol; 2020; 11():584680. PubMed ID: 33193401
[TBL] [Abstract][Full Text] [Related]
12. Surprisingly Effective Priming of CD8
Croft S; Wong YC; Smith SA; Flesch IEA; Tscharke DC
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759313
[TBL] [Abstract][Full Text] [Related]
13. Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy.
Qin L; Wang S; Dominguez D; Long A; Chen S; Fan J; Ahn J; Skakuj K; Huang Z; Lee A; Mirkin C; Zhang B
Front Immunol; 2020; 11():1333. PubMed ID: 32733447
[TBL] [Abstract][Full Text] [Related]
14. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
15. Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density.
Gilfillan CB; Wang C; Mohsen MO; Rufer N; Hebeisen M; Allard M; Verdeil G; Irvine DJ; Bachmann MF; Speiser DE
Eur J Immunol; 2020 Apr; 50(4):505-514. PubMed ID: 31785153
[TBL] [Abstract][Full Text] [Related]
16. The effect of antigen dose on T cell-targeting vaccine outcome.
Billeskov R; Beikzadeh B; Berzofsky JA
Hum Vaccin Immunother; 2019; 15(2):407-411. PubMed ID: 30277831
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines: translation from mice to human clinical trials.
Maeng H; Terabe M; Berzofsky JA
Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
[TBL] [Abstract][Full Text] [Related]
18. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.
Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R
Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929
[TBL] [Abstract][Full Text] [Related]
20. Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses.
Leggatt GR
Vaccines (Basel); 2014 Jul; 2(3):537-48. PubMed ID: 26344744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
